Abstract Progression or recurrence due to resistance to aromatase inhibitors (AIs) is a significant clinical problem for a considerable number of patients with breast cancer. Programmed cell death 4 (PDCD4), a tumor suppressor protein, is targeted for degradation during tumor progression. In the current study, we aimed to examine PDCD4 expression and regulation in AI-resistant breast cancer cells, and its association with survival in patients with estrogen receptor (ER)-positive breast cancer. We determined PDCD4 expression levels in AI-resistant breast cancer cell lines and ER-positive breast cancer tumors, investigated the regulation of PDCD4 in AI-resistant breast cancer cell lines, and carried out a Kaplan-Meier survival analysis in two independent cohorts that included a total of 420 patients with ER-positive breast cancer. We found that PDCD4 expression was down-regulated in AI-resistant breast cancer cells, and this down-regulation was inversely correlated with activation of HER2 signaling. Moreover, lower expression of PDCD4 was significantly associated with HER2 positive status in ER-positive breast tumors. Down-regulation of PDCD4 was mediated through upregulation of HER2 via the mitogen-activated protein kinase (MAPK), protein kinase B (PKB/AKT), and miR-21 in AI-resistant breast cancer cells. MiR-21 inhibitor and the ER down-regulator fulvestrant induced PDCD4 expression and decreased cell proliferation in AI-resistant breast cancer cells. Furthermore, forced overexpression of PDCD4 resensitized AI-resistant cells to AI or hormone deprivation. Finally, we identified that down-regulation of PDCD4 was associated with a lower rate of disease-free survival in patients with ER-positive breast cancer and high histologic grade of breast tumors. In summary, our study shows that expression of PDCD4 is down-regulated by HER2 signaling in AI-resistant breast cancer. Down-regulation of PDCD4 is associated with AI resistance and a poor prognosis in patients with ER-positive breast cancer. 
Introduction
Endocrine therapy plays a central role in the treatment of patients with estrogen receptor (ER)-positive advanced breast cancer. In postmenopausal patients, selective aromatase inhibitors (AIs) (i.e., letrozole, anastrozole, and exemestane), which block the peripheral conversion of androgens into estrogens and reduce the estrogen levels, are used as first-line treatment [1] . Unfortunately, resistance to AI treatment is present in a considerable number of patients, who may have no response to AIs (primary or de novo resistance) or will eventually relapse despite an initial response (acquired resistance) [1] .
There is increasing evidence suggesting that cross-talk between the ER and the human epidermal growth factor receptor 2 (HER2) signaling is involved in the development of resistance to AIs. ER can interact with and activate HER2 and its downstream signaling intermediates, such as the mitogen-activated protein kinase (MAPK) and protein kinase B (PKB/AKT) [2] . On the other hand, activation of HER2 signaling pathway, including the MAPK and phosphatidylinositol 3 0 -kinase (PI3K)/AKT, can phosphorylate and activate ER in a ligand-independent manner [3, 4] , which has been implicated in endocrine therapy resistance [5] [6] [7] . In patients treated with AIs, HER2 signaling is often up-regulated in breast tumors [8] . These findings suggest that targeting the ER pathway may lead to the up-regulation of HER2 pathway due to the extensive cross-talk, and ultimately result in endocrine resistance.
Programmed cell death 4 (PDCD4) is a tumor suppressor protein that was originally found to be induced by apoptosis [9, 10] . PDCD4 binds to the translation initiation factor eIF4A and inhibits its RNA-helicase activity, thus inhibiting protein translation [11, 12] . PDCD4 has been linked to tumorigenesis and tumor progression [13, 14] , and its expression has been found to be decreased in several types of cancers, including lung, colon, liver, and breast cancers [15] [16] [17] [18] . Like the well-known tumor suppressor phosphatase and tensin homolog (PTEN) [19] , PDCD4 has been established as an important functional target of the oncogenic microRNA, miR-21, which is commonly up-regulated in solid tumors and contributes to the down-regulation of PDCD4 [20, 21] .
Translational abberations has been shown to be associated with a poor prognosis in hormone receptor-positive breast cancer [22] . The expression of PDCD4, a translation inhibitor, is decreased during the progression of many cancers. We thus hypothesized that PDCD4 could be down-regulated during the development of AI resistance in breast cancer. In the current study, we found that PDCD4 expression was down-regulated by HER2 signaling in AIresistant breast cancer and associated with survival outcomes in patients with ER-positive breast cancer.
Materials and methods

Cell lines
Human breast cancer cell line MCF7-derived cell lines MCF7aro, LTEDaro, LET-R, HER2aro, AKTaro were generated in this laboratory and were characterized and described previously [23] [24] [25] . Details of culture conditions are provided in the Supplementary Appendix.
Antibodies and reagents
Antihuman PDCD4 (#9535), PTEN (#9188), p-HER2 (Tyr1248) (#2247), p-MAPK (#9101), MAPK (#9102), p-AKT (Ser473) (#9271), AKT (#9272), GAPDH (#2118) antibodies were obtained from Cell Signaling Technology. Antihuman HER2 antibody (#06-562) was from Abcam Inc. Antihuman ERa (HC-20) antibody (sc-543) was from Santa Cruz Biotechnology. The p44/42 MAPK siRNA (#6560) was obtained from Cell Signaling Technology. The nontargeting control siRNA (sc-37007) was from Santa Cruz Biotechnology. The AKT inhibitor MK-2206 was obtained from Selleck Chemicals. The ER downregulator fulvestrant was from Sigma-Aldrich. The antimiR-21 inhibitor and inhibitor negative control were purchased from Ambion.
Plasmid construct
The DNA fragment coding human PDCD4 was generated by RT-PCR using RNA from MCF7 cells as the template and the following oligonucleotides as the PCR primers (forward primer: 5 0 -CTGGGATCCCACCATGGATGTA-GAAAATGAGCAG-3 0 ; reverse primer: 5 0 -GGGGCTAGC TCAGTAGCTCTCTGGTTTAAGACG-3 0 ). The interest fragment was then cloned into the mammalian expression vector pMG-H2 using Bgl II-Nhe I restriction sites. The insert was verified by DNA sequencing.
Western blotting
Western blotting was performed as previously described [26] . Relative expression of proteins was normalized against the internal control GAPDH. Details are provided in the Supplementary Appendix.
Real-time PCR
The human PDCD4 gene was amplified using the forward primer 5 0 -ACAGGTGTATGATGTGGAGGA-3 0 and the reverse primer 5 0 -TTCTCAAATGCCCTTTCATCCAA-3 0 (PrimerBank ID 313760536c3) [27] . The ACTB (b-actin) gene was amplified using the forward primer 5 0 -CAC-CAACTGGGACGACAT-3 0 and the reverse primer 5 0 -GCACAGCCTGGATAGCAAC-3 0 . The miR-21 and U6 RNA were amplified using miR-21 or U6 RNA specific primer in conjunction with the universal PCR primer, all purchased from Quanta Biosciences. Experimental details are provided in the Supplementary Appendix.
Transfection
Details of transfection of cells with small interfering RNA (siRNA), estrogen responsive element (ERE) reporter plasmid, and human PDCD4 expression construct are provided in the Supplementary Appendix.
Luciferase reporter assay
Details of luciferase reporter assay are provided in the Supplementary Appendix.
Cell proliferation assay
Cell proliferation was measured by a 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Experimental details are provided in the Supplementary Appendix.
Gene expression analysis
PDCD4 differential expression analysis was performed in The Cancer Genome Atlas (TCGA) cohort in breast cancer patients with ER and HER2 status [28] . The differential expression p values were determined via t test using R [29] (http://www.R-project.org/). Disease-free survival analyses according to PDCD4 expression were determined in two independent prospective cohorts in breast cancer patients with ER status and disease-free survival outcomes [30, 31] . The high PDCD4 expression and low PDCD4 expression groups were segregated based on median expression values. Kaplan-Meier survival analysis was used to determine the disease-free survival differences between the high PDCD4 expression and low PDCD4 expression groups among patients with ER-positive breast cancer in two cohorts, and visualized by Kaplan-Meier plots and compared using Cox regression analysis, with p values calculated by log-rank test using the survival package in R [29] . Details are provided in the Supplementary Appendix.
Results
Down-regulation of PDCD4 expression is inversely correlated with activation of HER2 signaling in AIresistant breast cancer cells and ER-positive breast cancer tumors PDCD4, a tumor suppressor protein, has been linked to tumor progression [14] . To test our hypothesis that PDCD4 is down-regulated when breast cancer becomes resistant to AIs, we evaluated the mRNA and protein levels of PDCD4 in LET-R, a MCF7aro-derived breast cancer cell line resistant to the AI letrozole, and LTEDaro, a MCF7aro-derived breast cancer cell line after long-term estrogen deprivation (LTED). We found that both the mRNA and protein levels of PDCD4 were significantly decreased in LET-R and LTEDaro cells, as compared with the MCF7aro parental cells (Fig. 1a, b) . In contrast, the levels of PTEN, another tumor suppressor protein, were not significantly changed in LET-R or LTEDaro cells (Fig. 1b) .
Because the up-regulation of HER2 signaling pathway, including the MAPK and PI3K/AKT, has been implicated in endocrine therapy resistance [5] [6] [7] , we sought to determine whether PDCD4 expression is correlated with HER2 signaling in AI-resistant breast cancer cells. To investigate the activation state of the HER2 pathways in our LET-R and LTEDaro cell lines, we evaluated the levels of phosphorylated and total HER2, MAPK, and AKT by Western blotting. As shown in Fig. 1b , total HER2 expression and phospho-HER2, phospho-MAPK, and phospho-AKT were markedly increased in both LTEDaro and LET-R cells as compared with MCF7aro cells, which were inversely correlated with the PDCD4 expression.
To further determine the correlation between PDCD4 and HER2 signaling, we performed a differential expression analysis for PDCD4 in 406 patients with ER-positive breast cancer in the TCGA cohort [28] , including 318 patients with ER-positive and HER2-negative (ER? and HER2-) breast tumors, and 88 patients with ER-positive and HER2-positive (ER? and HER2?) breast tumors. We found that lower expression of PDCD4 was significantly associated with HER2 positive status (p = 0.0002, fold change = 1.4), supporting that down-regulation of PDCD4 is inversely correlated with the levels of HER2 in ERpositive breast cancer (Fig. 1c) .
Up-regulation of HER2 and MAPK signaling inhibits PDCD4 expression in AI-resistant breast cancer cells
Given the inverse correlation between PDCD4 expression and HER2 levels in both ER-positive breast cancer patients and AI-resistant breast cancer cells, we sought to determine whether up-regulation of the HER2 pathway decreases the expression of PDCD4. We thus did comparisons between MCF7aro and HER2aro, a MCF7-derived breast cancer cell line overexpressing HER2 and a model for primary resistance to AIs [25] . We found that HER2 expression and the phosphorylation of MAPK and AKT were remarkably increased, whereas both the PDCD4 protein and mRNA levels were significantly decreased in HER2aro cells as compared with MCF7aro cells (Fig. 2a, b ), indicating that up-regulation of HER2 signaling down-regulates PDCD4 expression.
To investigate whether the MAPK pathway is involved in the regulation of PDCD4, we determined whether reduction of MAPK expression by siRNA would alter the expression of PDCD4. We found that knockdown of MAPK significantly increased PDCD4 expression in both HER2aro and LTEDaro cells (Fig. 2c, d ), suggesting that PDCD4 is down-regulated by the MAPK pathway.
Activation of AKT inhibits PDCD4 expression in AIresistant breast cancer cells
Protein kinase S6K1, a downstream mediator of the PI3K/ AKT pathway, promotes the phosphorylation-dependent degradation of PDCD4 [32] . Because the AKT signaling pathway was up-regulated in AI-resistant breast cancer cells, we hypothesized that activation of AKT signaling could reduce the expression of PDCD4. To test this hypothesis, we did comparisons between MCF7aro and AKTaro, a MCF7-derived breast cancer cell line overexpressing AKT and a model for primary resistance to AIs [25] . We found that the phosphorylation of AKT was remarkably increased, whereas both the protein and mRNA levels of PDCD4 were significantly decreased in AKTaro cells as compared with MCF7aro cells (Fig. 3a, b) , suggesting that activation of AKT down-regulates PDCD4 expression.
To further confirm that AKT down-regulates PDCD4, we determined whether inhibition of AKT increases the expression of PDCD4. We found that treatment with MK-2206, an AKT inhibitor, markedly increased PDCD4 expression in both AKTaro and LTEDaro cells (Fig. 3c, d ), confirming that PDCD4 is down-regulated by AKT.
Up-regulation of miR-21 inhibits PDCD4 in AIresistant breast cancer cells PDCD4 has been established as a target of the oncogenic microRNA, miR-21, whose expression can be up-regulated by HER2 [20, 21, 33] . High miR-21 expression has been found to be associated with HER2 positive status in primary breast tumors [34] . As HER2 was up-regulated in our AI-resistant breast cancer cells, we wondered whether miR-21 is increased in these cells. We thus evaluated the levels of miR-21 in MCF7aro, HER2aro, LET-R, and LTEDaro cells by quantitative real-time PCR. We found that the levels of miR-21 were significantly increased in HER2aro, LET-R, and LTEDaro cells as compared with MCF7aro cells (Fig. 4a) .
Next, to investigate whether PDCD4 is a target of miR-21 in AI-resistant breast cancer cells, we determined whether inhibition of miR-21 increases the expression of PDCD4 in LET-R and LTEDaro cells. MiR-21 inhibitor significantly decreased the miR-21 levels in both LET-R and LTEDaro cells (Fig. 4b) . After the treatment with miR-21 inhibitor, PDCD4 levels were remarkably elevated in both LET-R and LTEDaro cells (Fig. 4c, d) . Interestingly, the levels of PTEN, another target of miR-21 [19] , were not changed (Fig. 4c, d ), suggesting that PDCD4 rather than PTEN is a target of miR-21 in AI-resistant breast cancer cells. 
Forced overexpression of PDCD4 resensitizes AIresistant breast cancer cells to AI or hormone deprivation
Activation of HER2 signaling pathway can lead to the activation of ER in a ligand-independent manner [3, 4] . Many groups, including us [24, 35, 36] , have shown that ERa is up-regulated and constitutively activated in AI-resistant breast cancer cells, especially in LTEDaro that had a low level of PDCD4 (Fig. 5a ). To test whether ERa plays a role in the down-regulation of PDCD4 in AI-resistant breast cancer cells, we examined the effect of fulvestrant, an ER down-regulator, on PDCD4 expression in LTEDaro cells. Fulvestrant treatment resulted in abolished ERa transcriptional activity, confirming that ERa in LTEDaro cells responds to fulvestrant (Fig. 5b) . The expression of PDCD4 was significantly increased following fulvestrant treatment (Fig. 5c) , which is consistent with a previous report [37] , indicating a role for PDCD4 in the treatment of AI-resistant breast cancer. Because PDCD4 is a target of miR-21, we determined the effect of fulvestrant on miR-21 expression. We found that miR-21 levels were increased in LTEDaro cells following fulvestrant treatment (Fig. 5d) , suggesting that the induced expression of PDCD4 by fulvestrant is not through miR-21, and that there may be a compensational increase of miR-21 after fulvestrant treatment.
As miR-21 was up-regulated in AI-resistant breast cancer cells and its expression was further increased following fulvestrant treatment, we sought to examine the effect of miR-21 inhibitor or a combination of miR-21 inhibitor and fulvestrant in AI-resistant breast cancer cells.
We found that miR-21 inhibitor treatment alone markedly decreased cell proliferation in LTEDaro cells (Fig. 5e) . Combination treatment of miR-21 inhibitor and fulvestrant further decreased cell proliferation in LTEDaro cells, in an additive manner (Fig. 5e) .
Next, to test whether increasing the expression of PDCD4, which is induced by miR-21 inhibitor and fulvestrant treatment, can resensitize AI-resistant breast cancer cells to AI, we generated a pMG-H2-PDCD4 expression construct. LET-R and LTEDaro cells were transfected with pMG-H2-PDCD4 expression construct or empty vector (Fig. 5f ). We found that forced overexpression of PDCD4 resensitized LET-R and LTEDaro to letrozole and hormone deprivation, respectively (Fig. 5g) . These data strongly suggest that PDCD4 plays a role in AI resistance of breast cancer.
Down-regulation of PDCD4 is associated with a poor prognosis in ER-positive breast cancer
To analyze the clinical relevance of PDCD4 downregulation in ER-positive breast cancer, we carried out a Kaplan-Meier survival analysis. Because data on diseasefree survival in the TCGA cohort are lacking, we did the analysis in other two independent cohorts that included a total of 420 patients with ER-positive breast cancer [30, 31] . This analysis showed that patients with a low level of PDCD4 expression had a worse prognosis than patients with a high level of PDCD4 expression. A Kaplan-Meier analysis of disease-free survival among 211 ER-positive breast cancer patients in the Ivshina cohort [30] showed that higher PDCD4 expression conferred a significant (Fig. 6a) . Similarly, lower PDCD4 expression was associated with a poor disease-free survival among 209 patients in the Wang cohort [31] with ER-positive breast tumors (p = 0.0004) (Fig. 6b) . These data suggest that PDCD4 expression has a prognostic value for patients with ER-positive breast cancer.
Next, we sought to determine the correlation between PDCD4 and histologic grade of breast tumors. Data on tumor grade are available in the Ivshina cohort [30] but not in the Wang cohort [31] . We thus performed a differential expression analysis for PDCD4 in 289 patients in the Ivshina cohort, including 68 patients with Elston grade 1 tumors, 166 patients with Elston grade 2 tumors, and 55 patients with Elston grade 3 tumors. The analysis showed a lower level of PDCD4 in patients with high grade (Elston grade 3) tumors than in patients with low grade (Elston grade1) tumors (p = 4.62e-08, fold change = 1.5) (Fig. S1 in the Supplementary Appendix).
In summary, our study shows that PDCD4 expression is down-regulated by HER2 via the MAPK, AKT, and miR-21 in AI-resistant breast cancer. Down-regulation of PDCD4 is associated with AI resistance and a poor prognosis in ER-positive breast cancer (Fig. 6c) .
Discussion
Progression or recurrence due to resistance to AIs is a significant clinical problem for a considerable number of ERpositive breast cancer patients. In this study, we found that the tumor suppressor PDCD4 was down-regulated in AIresistant breast cancer cells. We also identified an association between the down-regulation of PDCD4 and the upregulation of HER2 signaling in AI-resistant breast cancer cells and ER-positive breast tumors. More importantly, a poor prognosis was found in ER-positive breast cancer patients with a low level of PDCD4, further sustaining a potential contribution of PDCD4 to the development and/or outcome of AI resistance in breast cancer. PDCD4 has been known as a tumor suppressor [38] . PDCD4 inhibits protein translation by binding to the translation initiation factor eIF4A and suppressing its activity [11, 12] . PDCD4 is targeted for degradation during tumor progression [14] . Breast cancer may progress or relapse because of resistance to AIs, and we demonstrated that PDCD4, a tumor suppressor, was down-regulated in AI-resistant breast cancer cells, and that forced overexpression of PDCD4 resensitized AI-resistant cells to AI or hormone deprivation. Furthermore, our survival analysis suggests that the downregulation of PDCD4 is clinically significant in breast cancer, since ER-positive breast cancer patients with a low level of PDCD4 tend to have a lower rate of disease-free survival based on microarray datasets in two independent patient cohorts [30, 31] that included a total of 420 patients. Consistent with our finding that low PDCD4 predicts a poor prognosis, Meric-Bernstam et al. have shown that low protein expression of PDCD4 is associated with worse overall survival but not recurrence-free survival in hormone receptorpositive breast cancer with the use of reverse phase protein arrays in 190 patients [22] . In addition, our study showed that low PDCD4 was significantly correlated with high histologic grade of breast tumors. Identification of reliable biomarkers that can be used to predict patient outcomes ensures more effective clinical management, and we propose that PDCD4 is such a biomarker in ER-positive breast cancer.
Up-regulation of HER2 signaling pathway has been found in AI-resistant breast cancer cells [5, 6] and breast tumors of patients treated with AIs [8] . HER2 signaling promotes cell proliferation and survival through the MAPK and PI3K/AKT pathways [39] . In our study, we found an inverse correlation between the PDCD4 expression and the activation of HER2 signaling pathways in AI-resistant breast cancer cells. Consistently, our differential gene expression analysis in the TCGA patient cohort [28] showed that lower expression of PDCD4 was significantly associated with HER2 positive status in patients with ER-positive breast cancer. We further demonstrated that HER2 downregulated PDCD4 via the MAPK, AKT, and miR-21 in AIresistant breast cancer cells. These findings strongly suggest that the down-regulation of PDCD4 is, at least in part, mediated through HER2 in AI-resistant breast cancer. In addition to HER2 signaling, other growth factor receptors, such as the insulin-like growth factor 1 receptor (IGF1R) [40, 41] and epidermal growth factor receptor (EGFR) [42] , have been associated with AI resistance. As these growth factor receptors can also activate the MAPK and PI3K/ AKT [43] , further studies are needed to investigate whether they are involved in the down-regulation of PDCD4.
Up-regulated and constitutively activated ERa has been shown to play a role in AI resistance [24, 35, 36] . PDCD4 can be induced by anti-estrogen treatment [37] . Consistently, our results showed that PDCD4 expression was significantly increased following fulvestrant treatment in AI-resistant breast cancer cells, suggesting that ERa may play a role in the down-regulation of PDCD4. The mechanisms of ERa regulation of PDCD4 might be complicated. We evaluated the effect of fulvestrant on miR-21 expression. Interestingly, we found that fulvestrant increased the expression of miR-21 rather than decreasing it, which is consistent with a report showing that estradiol represses the expression of miR-21 by activating ER in MCF7 cells [44] . These findings suggest that the regulation of PDCD4 by ERa is not through miR-21 and that there are other mechanisms responsible for it. One possibility is that ERa activation can activate PI3K/AKT/p-70S6K signaling [45] and even can directly transcriptionally up-regulate the expression of S6K1 [46] , which promotes the phosphorylation-dependent degradation of PDCD4 [32] . Our results showed that activation of AKT down-regulated PDCD4 expression in support of this possible mechanism. In addition, activating mutations of ESR1, which encodes ERa, have been identified in hormone-resistant metastatic breast cancer [47, 48] . It is possible that ERa mutant signaling may also play a role in the regulation of PDCD4, but we do not know whether it is involved in our AI-resistant models. Therefore, the mechanisms of ERa regulation of PDCD4 need to be further investigated.
Down-regulation of PDCD4 is often associated with upregulation of the oncogenic microRNA miR-21 [20, 21] . High miR-21 expression is associated with HER2 positive status in primary breast tumors [34] , and overexpression of HER2 significantly induces miR-21 in breast cancer cells [33] . Consistent with the up-regulation of HER2 signaling, we found an increase of miR-21 levels in AI-resistant breast cancer cells. miR-21 has also been linked to MAPK or PI3K/AKT pathways [49, 50] , and the two major pathways can be activated by HER2. There is increasing evidence suggesting that microRNAs are involved in AI resistance [51] [52] [53] , including miR-21, which has been shown to have elevated expression following combination treatment of tamoxifen and exemestane [52] . In this study, we found that treatment with miR-21 inhibitor remarkably increased the expression of PDCD4 and decreased cell proliferation in AI-resistant breast cancer cells. Moreover, we showed that forced overexpression of PDCD4 resensitized AI-resistant cells to AI or hormone deprivation. These data suggest potential roles of miR-21 and PDCD4 in AI resistance of breast cancer.
In conclusion, our study shows that the tumor suppressor PDCD4 expression is down-regulated by HER2 signaling in AI-resistant breast cancer. The down-regulation of PDCD4 is associated with AI resistance and may predict a poor prognosis in patients with ER-positive breast cancer.
